FDA grants emergency use authorization to J&J COVID-19 vaccine
MANILA, Philippines — Johnson & Johnson has secured an emergency use authorization (EUA) for its Janssen COVID-19 vaccine from the Food and Drug Administration (FDA), Secretary Carlito Galvez Jr., the country’s vaccine manager, said Monday.
“Regarding Johnson & Johnson, we thank the FDA because its EUA has been released. Now, we have five vaccines with an EUA,” Galvez said in Filipino during a pre-recorded meeting of President Rodrigo Duterte with his Cabinet.
“The only ones left [with an EUA] are Moderna at Novovax,” he added.
The four other vaccines that have secured an EUA are those developed by Sinovac BioTech, AstraZeneca, Pfizer-BioNTech, and Russia’s Gamaleya Institute.
The Philippines has already reserved six million doses of J&J’s single-shot vaccine, Philippine Ambassador to the United States Jose Romualdez previously said.
J&J’s vaccine is said to be 85.4 percent effective in preventing the severe respiratory disease.
RELATED STORY:
What you need to know about the Johnson & Johnson vaccine
